Determinants of Skeletal Fragility in Acromegaly: a Systematic Review and Meta-analysis

Overview

Journal Pituitary

Specialty Endocrinology

Date 2022 Jul 22

PMID 35867180

Authors

Claudia Ribeiro de Moura

Sara Campos Lopes

Ana Margarida Monteiro

Affiliations

Soon will be listed here.

Abstract

Purpose: Vertebral fractures (VFs) are a potential complication in acromegaly. However, the etiology of this skeletal fragility is unknown. This review aimed to evaluate the effect of acromegaly on VFs, bone turnover, areal bone mineral density (aBMD), and bone quality/microarchitecture. The effect of disease activity and gonadal status in these determinants of skeletal fragility was also evaluated.

Methods: Articles published in English until September 6, 2020 on PubMed and Embase that reported at least one determinant of skeletal fragility in acromegalic patients, were included. Odds ratio (OR) to evaluate the risk of VFs and the standardized mean difference (SMD) to evaluate bone turnover, aBMD and bone quality/microarchitecture were calculated.

Results: Fifty-eight studies met eligibility criteria, assembling a total of 2412 acromegalic patients. Of these, 49 studies were included in the meta-analysis. Acromegalic patients, when compared to non-acromegalic patients, had higher risk of VFs [OR 7.00; 95% confidence interval (CI) 2.80-17.52; p < 0.0001], higher bone formation (SMD 1.14; 95% CI 0.69-1.59; p < 0.00001), higher bone resorption (SMD 0.60; 95% CI 0.09-1.10; p = 0.02) and higher aBMD at the femoral neck (SMD 0.36; 95% CI 0.15-0.57; p = 0.0009). No significant differences were found regarding aBMD at lumbar spine. Considering the results of the different techniques evaluating bone quality/microarchitecture, the main reported alterations were a decrease in trabecular bone thickness and density, and an increase in trabecular separation. The presence of active disease and/or hypogonadism were associated with worst results.

Conclusion: Patients with acromegaly are at increased risk of VFs, mainly because of deterioration in bone microarchitecture.

Citing Articles

Impact of medical therapy for hormone-secreting Pituitary tumors on bone.

Freda P Pituitary. 2024; 27(6):860-873.

PMID: 38967763 DOI: 10.1007/s11102-024-01421-z.

DXA-derived lumbar bone strain index corrected for kyphosis is associated with vertebral fractures and trabecular bone score in acromegaly.

Jaafar S, Cristofolini G, Morenghi E, Rinaudo L, Birtolo M, Sala E Endocrine. 2024; 85(3):1319-1326.

PMID: 38809345 DOI: 10.1007/s12020-024-03863-8.

Long-term Pegvisomant Therapy of Acromegaly: Effects on Bone Density, Turnover and Microstructure Using HRpQCT.

Kuker A, Agarwal S, Shane E, Bicca J, Geer E, Cremers S J Endocr Soc. 2024; 8(6):bvae079.

PMID: 38715589 PMC: 11074588. DOI: 10.1210/jendso/bvae079.

New insights into the vitamin D/PTH axis in endocrine-driven metabolic bone diseases.

Di Filippo L, Bilezikian J, Canalis E, Terenzi U, Giustina A Endocrine. 2024; 85(3):1007-1019.

PMID: 38632163 DOI: 10.1007/s12020-024-03784-6.

Diagnosis and therapeutic approach to bone health in patients with hypopituitarism.

Kuliczkowska-Plaksej J, Zdrojowy-Welna A, Jawiarczyk-Przybylowska A, Gojny L, Bolanowski M Rev Endocr Metab Disord. 2024; 25(3):513-539.

PMID: 38565758 DOI: 10.1007/s11154-024-09878-w.

References

Katznelson L, Laws Jr E, Melmed S, Molitch M, Murad M, Utz A . Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014; 99(11):3933-51. DOI: 10.1210/jc.2014-2700. View

Vilar L, Vilar C, Lyra R, Lyra R, Naves L . Acromegaly: clinical features at diagnosis. Pituitary. 2016; 20(1):22-32. DOI: 10.1007/s11102-016-0772-8. View

Wassenaar M, Biermasz N, Hamdy N, Zillikens M, van Meurs J, Rivadeneira F . High prevalence of vertebral fractures despite normal bone mineral density in patients with long-term controlled acromegaly. Eur J Endocrinol. 2011; 164(4):475-83. DOI: 10.1530/EJE-10-1005. View

Mazziotti G, Bianchi A, Bonadonna S, Cimino V, Patelli I, Fusco A . Prevalence of vertebral fractures in men with acromegaly. J Clin Endocrinol Metab. 2008; 93(12):4649-55. DOI: 10.1210/jc.2008-0791. View

Giustina A, Mazziotti G, Canalis E . Growth hormone, insulin-like growth factors, and the skeleton. Endocr Rev. 2008; 29(5):535-59. PMC: 2726838. DOI: 10.1210/er.2007-0036. View

Zgliczynski W, Kochman M, Misiorowski W, Zdunowski P . In acromegaly, increased bone mineral density (BMD) is determined by GH-excess, gonadal function and gender. Neuro Endocrinol Lett. 2007; 28(5):621-8. View

Giustina A . Acromegaly and Vertebral Fractures: Facts and Questions. Trends Endocrinol Metab. 2020; 31(4):274-275. DOI: 10.1016/j.tem.2020.01.011. View

Mazziotti G, Frara S, Giustina A . Pituitary Diseases and Bone. Endocr Rev. 2018; 39(4):440-488. DOI: 10.1210/er.2018-00005. View

Hou Y, Hu M, Zhou H, Li C, Li X, Liu X . Neuronal Signal Transduction-Involved Genes in Pig Hypothalamus Affect Feed Efficiency as Revealed by Transcriptome Analysis. Biomed Res Int. 2019; 2018:5862571. PMC: 6327278. DOI: 10.1155/2018/5862571. View

10.

Higgins J, Thompson S, Deeks J, Altman D . Measuring inconsistency in meta-analyses. BMJ. 2003; 327(7414):557-60. PMC: 192859. DOI: 10.1136/bmj.327.7414.557. View

11.

Brozek J, Akl E, Alonso-Coello P, Lang D, Jaeschke R, Williams J . Grading quality of evidence and strength of recommendations in clinical practice guidelines. Part 1 of 3. An overview of the GRADE approach and grading quality of evidence about interventions. Allergy. 2009; 64(5):669-77. DOI: 10.1111/j.1398-9995.2009.01973.x. View

12.

Stepan J, Marek J, Havranek T, Dolezal V, Pacovsky V . Bone isoenzyme of serum alkaline phosphatase in acromegaly. Clin Chim Acta. 1979; 93(3):355-63. DOI: 10.1016/0009-8981(79)90285-7. View

13.

de la Piedra C, Larranaga J, Castro N, Horcajada C, RAPADO A, Herrera Pombo J . Correlation among plasma osteocalcin, growth hormone, and somatomedin C in acromegaly. Calcif Tissue Int. 1988; 43(1):44-5. DOI: 10.1007/BF02555167. View

14.

Diamond T, Nery L, Posen S . Spinal and peripheral bone mineral densities in acromegaly: the effects of excess growth hormone and hypogonadism. Ann Intern Med. 1989; 111(7):567-73. DOI: 10.7326/0003-4819-111-7-567. View

15.

Ho P, Fig L, Barkan A, Shapiro B . Bone mineral density of the axial skeleton in acromegaly. J Nucl Med. 1992; 33(9):1608-12. View

16.

Marazuela M, Astigarraga B, Tabuenca M, Estrada J, Marin F, Lucas T . Serum bone Gla protein as a marker of bone turnover in acromegaly. Calcif Tissue Int. 1993; 52(6):419-21. DOI: 10.1007/BF00571329. View

17.

KOTZMANN H, Bernecker P, Hubsch P, Pietschmann P, Woloszczuk W, Svoboda T . Bone mineral density and parameters of bone metabolism in patients with acromegaly. J Bone Miner Res. 1993; 8(4):459-65. DOI: 10.1002/jbmr.5650080410. View

18.

Piovesan A, Terzolo M, Reimondo G, Pia A, Codegone A, Osella G . Biochemical markers of bone and collagen turnover in acromegaly or Cushing's syndrome. Horm Metab Res. 1994; 26(5):234-7. DOI: 10.1055/s-2007-1001672. View

19.

Scillitani A, Chiodini I, Carnevale V, Giannatempo G, Frusciante V, Villella M . Skeletal involvement in female acromegalic subjects: the effects of growth hormone excess in amenorrheal and menstruating patients. J Bone Miner Res. 1997; 12(10):1729-36. DOI: 10.1359/jbmr.1997.12.10.1729. View

20.

Bolanowski M, Wielgus W, Milewicz A, Marciniak R . Axial bone mineral density in patients with acromegaly. Acad Radiol. 2000; 7(8):592-4. DOI: 10.1016/s1076-6332(00)80573-5. View